




RealRate

PHARMACEUTICAL 2021

Avadel Pharmaceuticals PLC
Rank 194 of 394



The relative strengths and weaknesses of Avadel Pharmaceuticals PLC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Avadel Pharmaceuticals PLC compared to the market average is the variable Assets, increasing the Economic Capital Ratio by 42% points. The greatest weakness of Avadel Pharmaceuticals PLC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 131% points.

The company's Economic Capital Ratio, given in the ranking table, is 273%, being 16% points above the market average of 256%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	263,454	Assets	311,637
Cost of Goods Sold	5,742	Liabilities	149,371
Intangible Assets	16,836	Expenses	17,403
Liabilities, Current	15,109	Revenues	22,334
Liabilities, Non-Current	134,262	Stockholders Equity	162,266
Other Assets	30,988	Net Income	7,028
Other Compr. Net Income	1,755	Comprehensive Net Income	7,906
Other Expenses	-41,186	BaseVar	252,298
Other Liabilities	0	ECR before LimitedLiability	157%
Other Net Income	2,097	Economic Capital Ratio	273%
Other Revenues	22,334		
Property and Equipment	359		
Research and Development	20,442		
Selling, General and Administrative Expense	32,405		